Racial and ethnic differences in adjuvant hormonal therapy use

Journal of Women's Health

Volumn 21, Issue 9, 2012, Pages 950-958

  Livaudais, Jennifer C ^a   Li, Christopher ^b,c   John, Esther M ^d   Terry, Mary Beth ^e   Daly, Mary ^f   Buys, Saundra S ^g   Habel, Laurel ^h   Thompson, Beti ^b,c   Yanez, N David ^c   Coronado, Gloria D ⁱ  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Och Spine at New York Presbyterian Hospitals   (United States)

^f FOX CHASE CANCER CENTER   (United States)

^g UNIVERSITY OF UTAH   (United States)

^h DIVISION OF RESEARCH   (United States)

ⁱ CENTER FOR HEALTH RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BREAST CANCER; CONTROLLED STUDY; ETHNIC DIFFERENCE; FEMALE; GENETIC SUSCEPTIBILITY; HORMONAL THERAPY; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RACE DIFFERENCE; RISK; SELF REPORT;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CALIFORNIA; CHEMOTHERAPY, ADJUVANT; DRUG UTILIZATION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HEALTH STATUS DISPARITIES; HEALTHCARE DISPARITIES; HUMANS; LOGISTIC MODELS; MIDDLE AGED; ODDS RATIO; REGISTRIES; SELF REPORT; SOCIOECONOMIC FACTORS; UNITED STATES; YOUNG ADULT;

EID: 84865705954     PISSN: 15409996     EISSN: 1931843X     Source Type: Journal    
DOI: 10.1089/jwh.2011.3254     Document Type: Article

References (24)

1. Jemal A, Clegg LX, Ward E, et al. Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer 2004;101:3-27.
2. Chu KC, Lamar CA, Freeman HP. Racial disparities in breast carcinoma survival rates: Separating factors that affect diagnosis from factors that affect treatment. Cancer 2003;97:2853-2860.
3. Li CI, Malone KE, Daling JR. Differences in breast cancer stage, treatment, and survival by race and ethnicity. Arch Intern Med 2003;163:49-56.
4. Ooi SL, Martinez ME, Li CI. Disparities in breast cancer characteristics and outcomes by race/ethnicity. Breast Cancer Res Treat 2011;127:729-738.
5. Banerjee M, George J, Yee C, Hryniuk W, Schwartz K. Disentangling the effects of race on breast cancer treatment. Cancer 2007;110:2169-2177.
6. Hershman D, McBride R, Jacobson JS, et al. Racial disparities in treatment and survival among women with early-stage breast cancer. J Clin Oncol 2005;23:6639-6646.
7. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005;365:1687-1717.
8. Tamoxifen for early breast cancer: An overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998;351:1451-1467.
9. Freedman RA, Virgo KS, He Y, et al. The association of race/ethnicity, insurance status, and socioeconomic factors with breast cancer care. Cancer 2011;117:180-189.
10. Prehn AW, Topol B, Stewart S, Glaser SL, O'Connor L, West DW. Differences in treatment patterns for localized breast carcinoma among Asian/Pacific islander women. Cancer 2002;95:2268-2275.
11. Harlan LC, Clegg LX, Abrams J, Stevens JL, Ballard-Barbash R. Community-based use of chemotherapy and hormonal therapy for early-stage breast cancer: 1987-2000. J Clin Oncol 2006;24:872-877.
12. John EM, Hopper JL, Beck JC, et al. The Breast Cancer Family Registry: An infrastructure for cooperative multinational, interdisciplinary and translational studies of the genetic epidemiology of breast cancer. Breast Cancer Res 2004;6:R375-389.
13. John EM, Miron A, Gong G, et al. Prevalence of pathogenic BRCA1 mutation carriers in 5 US racial/ethnic groups. JAMA 2007;298:2869-2876.
14. Ma H, Wang Y, Sullivan-Halley J, et al. Breast cancer receptor status: Do results from a centralized pathology lab-oratory agree with SEER registry reports? Cancer Epidemiol Biomarkers Prev 2009;18:2214-2220.
15. Neuhausen SL, Ozcelik H, Southey MC, et al. BRCA1 and BRCA2 mutation carriers in the Breast Cancer Family Registry: An open resource for collaborative research. Breast Cancer Res Treat 2009;116:379-386.
16. Bickell NA, Wang JJ, Oluwole S, et al. Missed opportunities: Racial disparities in adjuvant breast cancer treatment. J Clin Oncol 2006;24:1357-1362.
17. Short LJ, Fisher MD, Wahl PM, et al. Disparities in medical care among commercially insured patients with newly diagnosed breast cancer: Opportunities for intervention. Cancer 2010;116:193-202.
18. Pruthi S, Boughey JC, Brandt KR, et al. A multidisciplinary approach to the management of breast cancer, part 2: Therapeutic considerations. Mayo Clin Proc 2007;82:1131-1140.
19. Coates AS, Keshaviah A, Thurlimann B, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: Update of study BIG 1-98. J Clin Oncol 2007;25:486-492.
20. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005;365:60-62.
21. Hershman DL, Shao T, Kushi LH, et al. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat 2011;126:529-537.
22. Maunsell E, Drolet M, Ouhoummane N, Robert J. Breast cancer survivors accurately reported key treatment and prognostic characteristics. J Clin Epidemiol 2005;58:364-369.
23. Schootman M, Jeffe DB, West MM, Aft R. Self-report by elderly breast cancer patients was an acceptable alternative to Surveillance, Epidemiology, and End Results (SEER) abstract data. J Clin Epidemiol 2005;58:1316-1319.
24. Phillips KA, Milne RL, Buys S, et al. Agreement between self-reported breast cancer treatment and medical records in a population-based Breast Cancer Family Registry. J Clin Oncol 2005;23:4679-4686.